<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485810</url>
  </required_header>
  <id_info>
    <org_study_id>5293</org_study_id>
    <secondary_id>F1D-JE-RA01</secondary_id>
    <nct_id>NCT00485810</nct_id>
  </id_info>
  <brief_title>Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia</brief_title>
  <official_title>A Study Examining Clinical Therapeutic Dose of Rapid Acting Intra-Muscular Olanzapine in Japanese Agitated Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the clinical therapeutic dose in Japanese agitated
      patients with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to examine the safety and efficacy of the clinical therapeutic dose of IM olanzapine (7.5 mg/inj and 10 mg/inj) in Japanese agitated patients with schizophrenia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the efficacy of IM olanzapine by evaluating change from baseline to 24 hours following the first IM injection in the PANSS Excited Component Total Score and the ACES</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the characteristics of sedation for each treatment group based on the ACES score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine a frequency of patients who needed second injection</measure>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine Hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients at least 20 years of age and less than 65 years old

          -  Patients must be inpatients during the study

          -  Patients must have a diagnosis of schizophrenia as per the DSM-IV, as determined by
             the investigator

          -  Patients must be considered by the investigator to be clinically agitated and to be
             clinically appropriate candidates for the treatment with intramuscular (IM) medication

          -  Patients must have a minimum total score of greater than or equal to 14 on the 5 items
             of the PANSS-EC and at least one individual item score of greater than or equal to 4
             using the 1-7 scoring system, prior to the first IM injection of study drug

        Exclusion Criteria:

          -  Serious, unstable illnesses such that death is anticipated within 1 year or intensive
             care unit hospitalization for the disease is anticipated within 6 months. This
             includes hepatic (specifically any degree of jaundice), renal, gastroenterologic,
             respiratory, cardiovascular (including ischemic heart disease), endocrinologic,
             neurologic, immunologic, or hematologic diseases

          -  Known history of seizures; however, a patient whose etiology is identifiable and has
             been resolved may be enrolled

          -  Known history of diabetes mellitus, complications of diabetes mellitus, or potential
             diabetes mellitus as defined by patients with single blood glucose measurement based
             on site tests; patients with values greater than or equal to 140 mg/dL (non-fasting)
             or greater than or equal to 110 mg/dL (fasting) must be excluded from the study

          -  History of allergic reaction or intolerance to olanzapine

          -  Have received treatment with psychostimulants or reserpine within 1 week prior to
             study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2007</study_first_submitted>
  <study_first_submitted_qc>June 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2007</study_first_posted>
  <last_update_submitted>June 11, 2007</last_update_submitted>
  <last_update_submitted_qc>June 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

